Nodular lichen myxoedematous: a new adverse event associated with ustekinumab

Australas J Dermatol. 2020 Aug;61(3):e344-e345. doi: 10.1111/ajd.13291. Epub 2020 Apr 14.

Abstract

Nodular lichen myxoedematosus is a localised form of lichen myxoedematosus, a chronic idiopathic cutaneous mucinosis of known aetiology. Ustekinumab is a human interleukin-12/23 monoclonal antibody that could directly or indirectly increase mucin production. Herein, we report for the first time a case of nodular lichen myxoedematosus associated with ustekinumab.

Keywords: biological therapy; drug toxicity; interleukin-23; mucins; scleromyxoedema; toxicity; ustekinumab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Crohn Disease / drug therapy
  • Drug Eruptions / etiology*
  • Drug Eruptions / pathology
  • Gastrointestinal Agents / adverse effects*
  • Humans
  • Lichenoid Eruptions / chemically induced*
  • Lichenoid Eruptions / pathology
  • Male
  • Mucinoses / chemically induced*
  • Mucinoses / pathology
  • Ustekinumab / adverse effects*

Substances

  • Gastrointestinal Agents
  • Ustekinumab